Home Cart 0 Sign in  
X

[ CAS No. 923595-49-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 923595-49-7
Chemical Structure| 923595-49-7
Chemical Structure| 923595-49-7
Structure of 923595-49-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 923595-49-7 ]

Related Doc. of [ 923595-49-7 ]

Alternatived Products of [ 923595-49-7 ]

Product Details of [ 923595-49-7 ]

CAS No. :923595-49-7 MDL No. :MFCD11044749
Formula : C6H3ClIN3 Boiling Point : -
Linear Structure Formula :- InChI Key :IWHCPHZAMFSDFM-UHFFFAOYSA-N
M.W : 279.47 Pubchem ID :53249897
Synonyms :

Calculated chemistry of [ 923595-49-7 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 50.71
TPSA : 30.19 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.61 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.91
Log Po/w (XLOGP3) : 1.97
Log Po/w (WLOGP) : 1.99
Log Po/w (MLOGP) : 2.1
Log Po/w (SILICOS-IT) : 2.09
Consensus Log Po/w : 2.01

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.42
Solubility : 0.106 mg/ml ; 0.000381 mol/l
Class : Soluble
Log S (Ali) : -2.23
Solubility : 1.65 mg/ml ; 0.0059 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.28
Solubility : 0.148 mg/ml ; 0.000528 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.45

Safety of [ 923595-49-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280 UN#:N/A
Hazard Statements:H317 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 923595-49-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 923595-49-7 ]
  • Downstream synthetic route of [ 923595-49-7 ]

[ 923595-49-7 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 6775-78-6 ]
  • [ 923595-49-7 ]
YieldReaction ConditionsOperation in experiment
90% With N-iodo-succinimide In chloroform at 20℃; Preparation of 6-chloro-3-iodoimidazo[1,2-b]pyridazine
6-chloroimidazo[1,2-b]pyridazine (2.0 g, 13.0 mmol, 1.0 equiv) in chloroform (20 mL) at room temperature was added N-iodosuccinimide (2.9 g, 13.0 mmol, 1.0 equiv) then stirred vigorously overnight.
The reaction mixture was diluted in water and extracted with ethyl acetate.
Purification using column chromatography gave 3.3 g of the yellow solid, 90percent: 1H NMR δ 8.21 (d, J=7.6 Hz, 1H), 7.96 (s, 1H), 7.41 (d, J=7.6 Hz, 1H).
75% With iodine In dimethyl sulfoxide at 20℃; for 36 h; Example 15 -3 Synthesis of 6-chloro-3-iodo-imidazo[1,2-b]pyridazine
6-chloroimidazo[1,2-b]pyridazine 1*a (28.0 g, 0.182 mol) was dissolved in DMSO (196 ml).
Iodine (55.0 g, 0.219 mol) was then added and the reaction mixture was stirred at room temperature for 36 hours.
The mixture was poured onto a saturated aqueous sodium bicarbonate solution (250 ml) and extracted with dichloromethane (2 x 250ml).
The organic layer was washed with an aqueous solution of sodium meta bisulfite (250 ml) followed by brine (250 ml).
It was then dried (Na2SO4) and evaporated under reduced pressure.
The residue was recrystallised from ethyl acetate to give 23 g (75 percent) of 6-chloro-3-iodo-imidazo[1,2-b]pyridazine 5* as an off white solid. 1H-NMR (400 MHz, DMSO-d6) : δ = 8.27 (1 H, d, J = 9.5 Hz), 8.02 (1 H, s), 7.46 (1 H, d, J = 9.5 Hz). LCMS-ESI (m/z); found 280.0 [M+H]+.
1.4 g With N-iodo-succinimide In acetonitrile at 60℃; for 10 h; Synthesis of 6-chloro-3-iodoimidazo[l , 2-bJpyridazine To a degassed solution of 6-chloroimidazo[l,2-b]pyridazine (1.0 g, 6.51 mmol) and NIS (2.2 g, 9.77 mmol) in MeCN (30 mL) was heated to 60 °C for 10 hours. The reaction mixture was cooled to RT and extract with DCM. The organics were washed with Na2S203 (aq), brine and dried over Na2S04. After concentrated, the crude product was purified by column (PE : EA = 5 : 1) to obtain 6-chloro-3-iodoimidazo[l,2-b]pyridazine (1.4 g, yield: 83percent). 1H- MR (CDC13, 400 MHz) δ 7.83 (s, 1H), 7.80 (d, J= 4.8 Hz, 1H), 7.04 (d, J= 9.6 Hz, 1H). MS(M+H)+: 280.
Reference: [1] Patent: US2014/256733, 2014, A1, . Location in patent: Page/Page column 0227; 0230-0231
[2] MedChemComm, 2018, vol. 9, # 10, p. 1733 - 1745
[3] Patent: EP2818471, 2014, A1, . Location in patent: Paragraph 0120; 0121
[4] Patent: WO2013/34048, 2013, A1, . Location in patent: Page/Page column 77; 78
[5] Journal of Medicinal Chemistry, 2014, vol. 57, # 6, p. 2789 - 2798
[6] Journal of the American Chemical Society, 2015, vol. 137, # 2, p. 592 - 595
Same Skeleton Products
Historical Records